Tirzepatide Compound Dosage Chart: The Weekly Schedule

Compounded tirzepatide has no FDA-approved labeling, which means there is no official tirzepatide compound dosage chart. What clinicians reference instead is the approved titration schedule below — and then individualize it. This page covers that schedule, what changes when a preparation is compounded, and the one difference between compounded vials that catches people out.

Tirzepatide compound dosage chart: the reference schedule

Treatment begins at 2.5 mg once weekly for four weeks. That first step is not intended to produce results on its own — it exists so the body can adapt. After four weeks the dose may increase in 2.5 mg increments, with at least four weeks at each step before the next increase.

Follow your prescription, not this chart. A compounded prescription is written for one patient, and yours may differ from the standard schedule for reasons specific to your history. Dose changes should come from the clinician managing your care.

Why there is no official compounded dosage chart

A dosing chart in the formal sense comes from FDA-approved labeling, which is the product of a review process covering safety, effectiveness, and manufacturing. A compounded preparation does not go through that process. It is prepared by a licensed pharmacy to fill an individual prescription, and it carries no approved labeling.

What that means practically: the schedule above is a clinical reference, not a regulatory instruction for the compounded product. It is the framework most clinicians work from because it is the only tirzepatide dosing schedule supported by trial evidence — but the prescription written for you is the authority, not the chart.

Compounded vials can differ in concentration

This is the difference that most often causes confusion, and it has no equivalent with the branded product. Because compounded preparations are made per prescription rather than manufactured to a single standard, the concentration — how many milligrams of tirzepatide are dissolved in each millilitre of solution — can vary between pharmacies, and sometimes between batches from the same pharmacy.

The consequence is that a prescribed dose in milligrams does not always correspond to the same volume drawn from every vial. A patient who switches pharmacies, or receives a refill prepared differently, can end up measuring by habit rather than by the current vial.

Why the dosage chart escalates so slowly

Gastrointestinal side effects with GLP-1 and GIP medications track closely with how quickly the dose rises, rather than with the absolute dose itself. The four-week minimum at each step is what makes higher doses tolerable later.

The first month can therefore feel uneventful. That is expected, and pushing through it faster tends to produce nausea and vomiting without improving the eventual outcome. Dehydration from severe vomiting is among the more common reasons people end up needing medical attention on these medications.

Side effects at each step of the dosage chart

The most common effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal discomfort — and they cluster in the days after a dose increase, often settling as the body adapts to a step.

• Boxed warning. Tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in rodents, and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This applies at every dose.
• Serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar when combined with certain diabetes medications, and hypersensitivity reactions.
• When to seek care. Severe or persistent abdominal pain, vomiting that prevents keeping fluids down, or signs of an allergic reaction warrant prompt medical attention rather than waiting for a scheduled check-in.

What to do about a missed dose

If your next scheduled dose is four or more days away, take the missed dose as soon as you remember. If it is sooner than that, skip it and resume your normal weekly schedule. Do not take two doses to make up for one.

If more than two consecutive weeks have been missed, contact your clinician before restarting. Tolerance fades during a gap, and resuming at your previous dose can bring back side effects you had already worked through — restarting from a lower step is often the safer path.

What these doses produced in clinical trials

SURMOUNT-1 was the pivotal 72-week weight-management trial. It studied the FDA-approved product, with lifestyle intervention in every arm. Results were dose-dependent, though the gain from 10 mg to 15 mg was smaller than the gain from 5 mg to 10 mg.

Two things these figures do not tell you. They come from branded tirzepatide, and no compounded preparation has been evaluated against those endpoints. And they say nothing about what happens afterward: a 2025 systematic review and meta-analysis in Lancet eClinicalMedicine pooling 18 randomized controlled trials and 3,771 adults found average weight regain of 5.63 kg following GLP-1 receptor agonist discontinuation.

Related dosing guides

• Semaglutide dosing chart — the weekly schedule for Wegovy and Ozempic.
• Microdosing tirzepatide chart — low-dose approaches and what the evidence supports.

Sources

• FDA-approved prescribing information for tirzepatide (Zepbound and Mounjaro).
• SURMOUNT-1: tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
• Weight regain after discontinuation of GLP-1 receptor agonists: systematic review and meta-analysis of 18 randomized controlled trials. Lancet eClinicalMedicine, 2025.